Literature DB >> 31167593

The Impact of Cognitive Impairment on Poststroke Outcomes: A 5-Year Follow-Up.

Daniela Rohde1, Eva Gaynor2, Margaret Large3, Lisa Mellon1, Patricia Hall3, Linda Brewer4, Kathleen Bennett1, David Williams4, Eamon Dolan5, Elizabeth Callaly6, Anne Hickey1.   

Abstract

AIM: To explore the impact of cognitive impairment poststroke on outcomes at 5 years.
METHODS: Five-year follow-up of the Action on Secondary Prevention Interventions and Rehabilitation in Stroke (ASPIRE-S) prospective cohort. Two hundred twenty-six ischemic stroke survivors completed Montreal Cognitive Assessments at 6 months poststroke. Outcomes at 5 years included independence in activities of daily living, receipt of informal care, quality of life, and depressive symptoms. Data were analyzed using logistic and linear regression models. Adjusted odds ratios (ORs; 95% confidence interval [CI]) and β coefficients (95% CI) are reported.
RESULTS: One hundred one stroke survivors were followed up at 5 years. Cognitive impairment at 6 months was independently associated with worse quality of life (B [95% CI]: -0.595 [-0.943 to -0.248]), lower levels of independence (B [95% CI]: -3.605 [-5.705 to -1.505]), increased likelihood of receiving informal care (OR [95% CI]: 6.41 [1.50-27.32]), and increased likelihood of depressive symptoms (OR [95% CI]: 4.60 [1.22-17.40]).
Conclusion: Cognitive impairment poststroke is associated with a range of worse outcomes. More effective interventions are needed to improve outcomes for this vulnerable group of patients.

Entities:  

Keywords:  activities of daily living; cerebrovascular disorders; cognitive impairment; depression; independence; quality of life; stroke

Mesh:

Year:  2019        PMID: 31167593     DOI: 10.1177/0891988719853044

Source DB:  PubMed          Journal:  J Geriatr Psychiatry Neurol        ISSN: 0891-9887            Impact factor:   2.680


  7 in total

1.  Relevance of Cognition and Emotion for Patient-Reported Quality of Life After Stroke in Working Age: An Observational Cohort Study.

Authors:  Daniela Pinter; Simon Fandler-Höfler; Viktoria Fruhwirth; Lisa Berger; Gerhard Bachmaier; Susanna Horner; Sebastian Eppinger; Markus Kneihsl; Christian Enzinger; Thomas Gattringer
Journal:  Front Neurol       Date:  2022-04-25       Impact factor: 4.086

2.  Stroke: time to address cognition.

Authors:  Eugene Yee Hing Tang; Louise Robinson; Christopher Price
Journal:  Br J Gen Pract       Date:  2021-02-25       Impact factor: 5.386

3.  Computer aided self-regulation learning and cognitive training improve generalization ability of patients with poststroke cognitive impairment.

Authors:  He Youze; Yang Ting; Bao Yaqi; Xiao Tianshen; Wu Tiecheng; Wu Jingsong
Journal:  Sci Rep       Date:  2021-12-17       Impact factor: 4.379

4.  The impact of stroke, cognitive function and post-stroke cognitive impairment (PSCI) on healthcare utilisation in Ireland: a cross-sectional nationally representative study.

Authors:  Isabelle Jeffares; Daniela Rohde; Frank Doyle; Frances Horgan; Anne Hickey
Journal:  BMC Health Serv Res       Date:  2022-03-29       Impact factor: 2.655

5.  Improvement of poststroke cognitive impairment by intermittent theta bursts: A double-blind randomized controlled trial.

Authors:  Wen Li; Qian Wen; Yu-Han Xie; An-Li Hu; Qing Wu; Yin-Xu Wang
Journal:  Brain Behav       Date:  2022-04-29       Impact factor: 3.405

6.  Cognitive impairment and medication adherence post-stroke: A five-year follow-up of the ASPIRE-S cohort.

Authors:  Daniela Rohde; Eva Gaynor; Margaret Large; Lisa Mellon; Kathleen Bennett; David J Williams; Linda Brewer; Patricia Hall; Elizabeth Callaly; Eamon Dolan; Anne Hickey
Journal:  PLoS One       Date:  2019-10-17       Impact factor: 3.240

7.  Acupuncture-related therapies for the poststroke cognitive impairment patients: A protocol for systematic review and network meta-analysis.

Authors:  Jun Tian; Li-Bing Hu; Miao Wu; Wen-Li Mo; Peng Wu; Yao-Hui Pu; Han-Chao Yang; Yun Fan
Journal:  Medicine (Baltimore)       Date:  2022-02-04       Impact factor: 1.817

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.